TFFP - TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19 2024 | Benzinga
FORT WORTH, Texas, March 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Harlan Weisman, M.D., Chief Executive Officer of TFF Pharmaceuticals will be presenting a corporate overview at the 36th Annual Roth Conference being held March 17-19, 2024 in Dana Point, California. Company management will also be participating in one-on-one meetings.
36th Annual Roth Conference – March 17-19, 2024
| Format: |
| TFF Pharmaceuticals, Inc. Company Presentation |
| Date/Time: |
| Monday, March 18, 2024, at 11:30 am PT |
| Participant: |
| Harlan Weisman, M.D., Chief Executive Officer |
| Location: |
| Dana Point, California |
| Link: |
| Register here |
A replay of the presentation will be available through the registration link for 90 days. Please contact your Roth representative to schedule one-on-one meetings with the management team during the conference.
ABOUT TFF PHARMACEUTICALS' THIN FILM FREEZING (TFF) TECHNOLOGY
TFF Pharmaceuticals' proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The TFF process is a particle engineering process designed to generate dry powder particles with advantageous properties for inhalation, as well ...